Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
7,341 total articles
Abeona Therapeutics Chief Executive Officer Seshadri Vishwas sold 29,985 shares on March 31, 2026, generating $131,481 under a Rule 10b5-1 plan. The company has reported its first commercial revenue following FDA approval of ZEVASKYN and recorded $5.8 million in total 2025 revenue. Analysts remain broadly positive but differ on near-term sales pace…
Yorktown IX Associates LLC, a 10 percent owner of Ramaco Resources, Inc. (NASDAQ:METC), disposed of 10,325 shares of Class B common stock in two transactions on March 27 and March 30, 2026, receiving roughly $111,532. After the sales, the firm indirectly continues to hold 1,216,317 Class B shares. The trades come as the stock trades at $15.46, refl…
Yorktown Energy Partners XI, L.P., a ten percent holder of Ramaco Resources, Inc. (NASDAQ: METC), disposed of 10,465 shares of Class B common stock in two transactions on March 27 and March 30, 2026, for roughly $113,044 in proceeds. The sales occurred at weighted average prices of $10.9327 and $10.3381, respectively. Following the disposals, Yorkt…
Yorktown XI Associates LLC, identified as a ten percent owner of Ramaco Resources, Inc. (NASDAQ:METC), disposed of 10,465 shares of Class B Common Stock in two transactions between March 27 and March 30, 2026, generating proceeds of $113,044. The disposition occurred against a backdrop of pronounced share-price volatility and a series of corporate …
Yorktown Energy Partners IX, L.P. — a holder of roughly 10% of Ramaco Resources, Inc. (NASDAQ: METC) — disposed of 10,325 Class B common shares in two trades between March 27 and March 30, 2026, generating $111,532 in proceeds. The disposals took place against a backdrop of recent corporate developments at Ramaco, including Q4 2025 results emphasiz…
Sharplink, Inc. Chief Financial Officer Robert Michael DeLucia executed a sale of 2,848 common shares on March 31, 2026, generating $17,696 at a per-share price of $6.2135. On the same day he also received 10,904 shares at no cash cost as restricted stock units vested. The transactions leave DeLucia with 93,098 directly held shares. The moves come …
Frances Arnold sold 102 shares of Alphabet Inc. Class C Capital Stock on March 30, 2026, for $275.19 per share, yielding proceeds of $28,069. The Class C shares have since risen to $287.56, about 4.5% above the sale price. Arnold continues to hold 18,316 Class C shares directly and multiple tranches of Google Stock Units (GSUs) with staggered vesti…
PubMatic Chief Executive Rajeev K. Goel sold 44,000 Class A shares on March 30, 2026, for about $356,188 under a predetermined Rule 10b5-1 plan. The same day he exercised options to buy 44,000 Class B shares at $1.11 and converted 44,000 Class B shares into Class A. The transaction occurred amid company buybacks and upbeat fourth-quarter 2025 resul…
Magnetar Financial LLC, a reported 10% owner of Wheeler Real Estate Investment Trust, Inc. (WHLR), sold 18,166 common shares across three transactions from March 27 to March 31, 2026, collecting $17,384. The trades came as WHLR shares traded near their 52-week low and followed recent corporate actions and executive changes at the REIT.
Zenas BioPharma Chief Executive Leon O. Moulder Jr. bought $1,021,140 of common stock in two transactions on March 30 and March 31, 2026, increasing his direct and indirect holdings. The insider purchases occurred as the share price slid nearly 12% over the prior week and 46% year-to-date. The company concurrently priced public offerings including …
Meredith Manning, Chief Commercial Officer at Soleno Therapeutics (SLNO), sold 7,522 shares on March 27, 2026, raising roughly $228,979 in a series of trades executed to satisfy tax withholding tied to restricted stock unit vesting. The insider retains 64,507 shares. The transaction occurred while SLNO shares hover near a 52-week low and follow a q…
Michael F. Huang, Soleno Therapeutics' Senior Vice President of Clinical Development, sold 6,582 shares on March 27, 2026 to satisfy tax withholding tied to vested restricted stock units. The transactions amounted to $200,364. The move occurs while the company reported a quarterly earnings beat, announced a new CFO, and saw analysts trim price targ…
Archer Aviation Inc. executive Eric Lentell sold 100,000 shares of Class A common stock under a prearranged 10b5-1 plan on March 26 and 27, 2026, generating $533,000. Filings show the sales were partially to cover tax liabilities tied to prior restricted stock unit settlements. The disclosure arrives as the company reported a fourth-quarter 2025 EP…
Melissa Marano Thompson, a director at ArrowMark Financial Corp (NASDAQ: BANX), purchased 1,500 common shares on March 27, 2026, at $18.765 per share, according to a Form 4 filing. The purchase totaled $28,147. ArrowMark is concurrently conducting a rights offering for up to 2,604,156 new common shares, with shareholders of record as of January 22 …
Strawberry Fields REIT director Stanford Gertz purchased 1,395 shares of the company’s common stock on March 18, 2026, paying $12.52 per share for a total of $17,465. The buy was conducted at a price above the current trading level of $11.90 and follows company announcements that include a $0.16 cash dividend for Q1 2026 and an increase in compensa…
Edgewise Therapeutics Chief Medical Officer Joanne M. Donovan sold 21,338 shares of common stock on March 31, 2026, for roughly $685,308 at prices between $32.00 and $32.35 under a Rule 10b5-1 plan. The transaction occurred as the stock traded near a 52-week high of $32.80 after a 94% six-month gain. Donovan simultaneously exercised options to buy …
Platinum Equity sold 1,348,314 shares of Ingram Micro Holding Corp on March 30, 2026, at $21.36 per share for a total of $28,799,987. The stake was transacted through a chain of affiliated vehicles controlled by Tom Gores. After the sale, Platinum Equity and related entities continue to beneficially own 197,104,541 shares. Separately, Ingram Holdco…
Adaptive Biotechnologies Corp. executive Julie Rubinstein sold 57,180 shares of common stock between March 27 and March 31, 2026, generating about $751,302 in proceeds from prices between $12.07 and $13.87. The transactions accompanied the exercise of stock options that produced 44,166 shares at $7.27 each. The trades were carried out under a Rule …
Palladyne AI Corp (NASDAQ: PDYN) Chief Financial Officer Trevor Thatcher disposed of 3,030 shares on March 30, 2026 to satisfy income tax obligations tied to recently vested restricted stock units. The sale, executed across multiple trades at prices between $5.295 and $5.6301 for an average of $5.5463, totaled $16,805. After the transactions, Thatc…
Palladyne AI Corp. (OTC: PDYN) Chief Legal Officer Stephen Sonne reported the sale of 3,471 common shares on March 30, 2026, in a Form 4 filing with the SEC. The shares were sold to satisfy income tax liabilities tied to vested restricted stock units and fetched a weighted average price of $5.5463, for total proceeds of $19,251. The stock has since…
Palladyne AI Corp. Chief Technology Officer Denis Garagic sold 15,149 shares of common stock on March 30, 2026, raising $84,020 at a weighted average price of $5.5463 to meet income tax liabilities tied to vested restricted stock units. The company has reported large year-over-year revenue gains for Q4 2025 and secured defense contracts, while its …
BFI Co., LLC, a roughly 10% holder of Phibro Animal Health Corp (NASDAQ: PAHC), sold 14,080 Class A shares on March 30-31, 2026 for about $756,833 under a Rule 10b5-1 plan adopted in December 2025. After the transactions, BFI Co. directly holds 38,120 shares. Jack Bendheim, Phibro’s President and CEO, exercises voting and dispositive power over BFI…
Kimberly D. Campos, chief investment officer and chief accounting officer at Universal Insurance Holdings (NASDAQ: UVE), sold 946 shares on March 31, 2026, for $34.12 per share, totaling $32,277. The Form 4 filing also reports an option exercise for 1,251 shares at a $0 strike and the withholding of 305 shares on March 27, 2026, to satisfy tax obli…
Daxor CORP Chief Financial Officer Robert J. Michel purchased 1,000 shares of company stock for $9.90 per share on March 31, 2026, bringing his direct holding to 21,050 shares. The transaction coincides with a stock price trading below the purchase level, recent operating revenue growth, an increase in net assets and a completed registered direct o…
C3.ai director Snabe Jim H. sold 10,000 Class A shares for $8.08 apiece and, on the same day, bought 10,000 Class A shares at $7.73, leaving him with a stated direct holding of 385,000 shares and an indirect stake of 28,000 through BJHS Invest ApS. The transactions come amid a difficult quarter for the enterprise AI company - fiscal Q3 results mate…
